Bryce Point Capital LLC purchased a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 44,063 shares of the company's stock, valued at approximately $845,000. Bryce Point Capital LLC owned approximately 0.06% of Viridian Therapeutics as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in VRDN. Charles Schwab Investment Management Inc. increased its position in Viridian Therapeutics by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company's stock valued at $11,744,000 after buying an additional 32,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Viridian Therapeutics by 17.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company's stock valued at $318,000 after acquiring an additional 2,036 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Viridian Therapeutics by 29.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 89,496 shares of the company's stock worth $2,036,000 after purchasing an additional 20,166 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Viridian Therapeutics during the third quarter valued at $149,000. Finally, Parkman Healthcare Partners LLC bought a new position in Viridian Therapeutics during the 3rd quarter valued at about $9,669,000.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company reiterated an "equal weight" rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $35.70.
View Our Latest Report on Viridian Therapeutics
Viridian Therapeutics Price Performance
NASDAQ:VRDN traded down $0.32 on Monday, reaching $11.68. 657,321 shares of the company's stock traded hands, compared to its average volume of 1,180,660. The firm has a market cap of $951.34 million, a PE ratio of -2.72 and a beta of 0.81. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $16.18 and a 200-day simple moving average of $19.40. Viridian Therapeutics, Inc. has a 12 month low of $10.93 and a 12 month high of $27.20.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
See Also
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
